Timber Pharmaceuticals - Investor Summit Group

Timber Pharmaceuticals

Ticker

TMBR

Website

Sector

Biotech

Tearsheet

Why Invest

Timber is well capitalized, has no debt and is fully funded - Two mid-late stage assets advancing toward commercialization - Multiple milestones over next twelve months including - Phase 3 study launch for TMB-001 expected mid-2022 - Data readout from Ph 2b study for TMB-002 expected in Q3 2022